A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions

• Main Authors: Alison Evans (Author), Debabrata Roy (Author), Sandeep Dhanda (Author), Samantha Lane (Author), Graça Coutinho (Author), Anuradha Kulasekaran (Author), David Miller-Shakesby (Author), Nagalakshmi Ramamoorthi (Author), Saad Shakir (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Flurbiprofen 8.75 mg lozenges and oromucosal sprays are used for symptomatic relief of sore throat in patients aged 12 years and over. The documented adverse events of flurbiprofen use include those related to its pharmacological actions, namely, increased risk of haemorrhagic events, ho...